Ascendia

  MARKET NEWS

First Patients Dosed With Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Bio-Rad Extends Range of Anti-Idiotypic Antibodies & Anti-Fc Mutation Antibodies for Bioanalysis & Drug Monitoring
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head & Neck Cancer
PannTheraPi Announces Significant Clinical Development & Strategic Milestones
ProImmune Collaborates With The University of Texas Medical Branch to Advance Infectious Disease Research
Symbiosis Expands Commercial Capabilities With Addition of New Stability Chamber
Vetter Strengthens its Global Clinical Manufacturing Network With Strategic Site Enhancements

  EXPERT CONTENT & RESOURCES

INTERVIEW - Advancing Regenerative Medicine for Chronic Disease

INTERVIEW - Advancing Regenerative Medicine for Chronic Disease

Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Portrait of Dr. Lara Zibners

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

  FEATURED EDITORIAL

  COMPANY PROFILE

Kenox Pharmaceuticals is a specialty contract development, manufacturing, and testing organization advancing nasal, inhalation, and ophthalmic drug products. We provide end-to-end support from early-stage research and formulation development through GMP fill-finish and analytical testing, enabling successful Phase I and II clinical trials. Our expertise includes both non-sterile and sterile drug–device combination products, ensuring quality and reliability across diverse development programs. Kenox is distinguished by deep technical knowledge, broad industry experience, and flexibility in managing complex device technologies, from conventional inhalers to advanced platforms such as Soft Mist inhalers. Click here for more.

VIDEOS

 

  WHITEPAPERS & WEBINARS

Drug Development & Delivery
WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 22 – Particle Design Technology
April 29 – Controlled Release